Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Antivir Ther
    July 2018
  1. OJHA RP, MacDonald BR, Chu TC, Fasanmi EO, et al
    Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection.
    Antivir Ther. 2018 Jul 3. doi: 10.3851/IMP3249.
    >> Share

    May 2018
  2. WEBER MD, Andrews E, Prince HA, Sykes C, et al
    Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.
    Antivir Ther. 2018 May 1. doi: 10.3851/IMP3236.
    >> Share

    March 2018
  3. MERLINI E, Galli L, Tincati C, Cannizzo ES, et al
    Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy.
    Antivir Ther. 2018 Mar 28. doi: 10.3851/IMP3234.
    >> Share

  4. MERLINI E, Galli L, Tincati C, Cannizzo ES, et al
    Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy.
    Antivir Ther. 2018 Mar 28. doi: 10.3851/IMP3239.
    >> Share

  5. TEERAANANCHAI S, Kerr SJ, Ruxrungtham K, Avihingsanon A, et al
    Loss to follow-up and associated factors of patients through the National AIDS Program in Thailand.
    Antivir Ther. 2018 Mar 27. doi: 10.3851/IMP3233.
    >> Share

  6. VAN DAM PM, van Geffen MW, Havenith TR, Posthouwer D, et al
    Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
    Antivir Ther. 2018 Mar 13. doi: 10.3851/IMP3229.
    >> Share

    February 2018
  7. BENGTSON AM, Pence BW, Eaton EF, Edwards JK, et al
    Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.
    Antivir Ther. 2018 Feb 9. doi: 10.3851/IMP3223.
    >> Share

    January 2018
  8. BIGLIANO P, Calcagno A, Lucchini A, Audagnotto S, et al
    The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment.
    Antivir Ther. 2018 Jan 26. doi: 10.3851/IMP3221.
    >> Share

  9. FIORENTINO M, Suzan-Monti M, Vilotitch A, Sagaon-Teyssier L, et al
    Renunciation of health care by people living with HIV in France is still associated with discrimination in health care services and social insecurity - results from the ANRS VESPA2 survey.
    Antivir Ther. 2018 Jan 23. doi: 10.3851/IMP3220.
    >> Share

  10. PETERS L, Mocroft A, Grint D, Moreno S, et al
    Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
    Antivir Ther. 2018 Jan 5. doi: 10.3851/IMP3218.
    >> Share

    November 2017
  11. FALUTZ J
    Frailty: is thy name.....universal? Evolving challenges of managing effectively treated older people living with HIV.
    Antivir Ther. 2017 Nov 24. doi: 10.3851/IMP3211.
    >> Share

  12. VENUTO CS, Lim J, Messing S, Hunt PW, et al
    Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
    Antivir Ther. 2017 Nov 24. doi: 10.3851/IMP3209.
    >> Share

  13. PATEL RR, Presti R, Harrison LC, Powderly WG, et al
    Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.
    Antivir Ther. 2017 Nov 23. doi: 10.3851/IMP3208.
    >> Share

    October 2017
  14. MORTIER V, Vancoillie L, Dauwe K, Staelens D, et al
    Meticulous plasma isolation is essential to avoid false low-level viraemia in Roche Cobas HIV-1 viral load assays.
    Antivir Ther. 2017 Oct 24. doi: 10.3851/IMP3203.
    >> Share

  15. BINDA F, Monge E, Simonetti FR, Zanchetta N, et al
    Primary HIV infection in patients with acute hepatitis B: a report of two cases.
    Antivir Ther. 2017 Oct 12. doi: 10.3851/IMP3201.
    >> Share

  16. HOPPE A, Giuliano M, Lugemwa A, Thompson JA, et al
    HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
    Antivir Ther. 2017 Oct 11. doi: 10.3851/IMP3200.
    >> Share

  17. ECKARD AR, O'Riordan MA, Rosebush JC, Lee ST, et al
    Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3199.
    >> Share

  18. JANTARABENJAKUL W, Anugulruengkitt S, Kasipong N, Thammajaruk N, et al
    Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically-suppressed HIV-1-infected adolescents.
    Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3198.
    >> Share

    September 2017
  19. SANTORO MM, Di Carlo D, Armenia D, Zaccarelli M, et al
    Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.
    Antivir Ther. 2017 Sep 22. doi: 10.3851/IMP3197.
    >> Share

  20. MARTINEZ-VEGA R, De La Mata NL, Kumarasamy N, Ly PS, et al
    Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE).
    Antivir Ther. 2017 Sep 21. doi: 10.3851/IMP3194.
    >> Share

  21. SHARMA A, Hoover DR, Shi Q, Holman S, et al
    Longitudinal study of falls among HIV-infected and uninfected women: the role of cognition.
    Antivir Ther. 2017 Sep 21. doi: 10.3851/IMP3195.
    >> Share

  22. SRINIVASA S, Lu MT, Fitch KV, Hallett TR, et al
    Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV.
    Antivir Ther. 2017 Sep 20. doi: 10.3851/IMP3193.
    >> Share

    August 2017
  23. GAGLIARDINI R, Bandera A, Zaccarelli M, Sterrantino G, et al
    3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
    Antivir Ther. 2017 Aug 11. doi: 10.3851/IMP3188.
    >> Share

  24. SAX P, DeJesus E, Wohl D, DeMorin J, et al
    Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA >/=1,000,000 copies/ml: a post hoc analysis of Phase 3 clinical trials.
    Antivir Ther. 2017 Aug 11. doi: 10.3851/IMP3187.
    >> Share

    July 2017
  25. YEOH HL, Cheng A, Palmer C, Crowe SM, et al
    Frailty in men living with HIV: a cross-sectional comparison of three frailty instruments.
    Antivir Ther. 2017 Jul 21. doi: 10.3851/IMP3185.
    >> Share

    June 2017
  26. SCHULTZE A, Paredes R, Sabin C, Phillips AN, et al
    The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.
    Antivir Ther. 2017 Jun 19. doi: 10.3851/IMP3178.
    >> Share

    May 2017
  27. SHILAIH M, Angst DC, Marzel A, Bonhoeffer S, et al
    Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV.
    Antivir Ther. 2017 May 12. doi: 10.3851/IMP3173.
    >> Share

    April 2017
  28. YAO AH, Moore CL, Lim PL, Molina JM, et al
    Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.
    Antivir Ther. 2017 Apr 27. doi: 10.3851/IMP3171.
    >> Share

  29. LUBEL J, Strasser S, Stuart KA, Dore G, et al
    Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir +/- ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
    Antivir Ther. 2017 Apr 19. doi: 10.3851/IMP3168.
    >> Share

  30. TROTTIER B, Lake JE, Logue K, Brinson C, et al
    Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Antivir Ther. 2017 Apr 12. doi: 10.3851/IMP3166.
    >> Share

  31. HANKINS CA, Koulla-Shiro S, Kilmarx P, Ferrari G, et al
    Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaounde, Cameroon.
    Antivir Ther. 2017 Apr 7. doi: 10.3851/IMP3165.
    >> Share

  32. VAN LUIN M, Ter Beest G, Wijnberger LE, Swanink CM, et al
    Zidovudine continuous infusion in an HIV-infected pregnant woman with a phobia of swallowing pills.
    Antivir Ther. 2017 Apr 3. doi: 10.3851/IMP3164.
    >> Share

    March 2017
  33. TATON A, Colson P, Dhiver C, Ruiz JM, et al
    Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.
    Antivir Ther. 2017 Mar 31. doi: 10.3851/IMP3163.
    >> Share

  34. AGUILERA A, Trastoy R, Barreiro P, Costa JJ, et al
    Decline and changing profile of hepatitis delta among injection drug users in Spain.
    Antivir Ther. 2017 Mar 29. doi: 10.3851/IMP3161.
    >> Share

  35. AFONSO P, Auclair M, Caron-Debarle M, Capeau J, et al
    Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.
    Antivir Ther. 2017 Mar 28. doi: 10.3851/IMP3160.
    >> Share

  36. ECKARD AR, Rosebush JC, O'Riordan MA, Graves CC, et al
    Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.
    Antivir Ther. 2017 Mar 22. doi: 10.3851/IMP3157.
    >> Share

  37. OLIVEIRA VH, Wiechmann SL, Narciso AM, Webel AR, et al
    Muscle strength is impaired in men but not in women living with HIV taking antiretroviral therapy.
    Antivir Ther. 2017 Mar 22. doi: 10.3851/IMP3159.
    >> Share

  38. PETOUMENOS K, Choi JY, Hoy J, Kiertiburanakul S, et al
    CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy.
    Antivir Ther. 2017 Mar 14. doi: 10.3851/IMP3155.
    >> Share

  39. LALLEY-CHARECZKO L, Clark D, Zuppa AF, Moorthy G, et al
    A case study of chewed Truvada(R) for PrEP maintaining protective drug levels as measured by a novel urine tenofovir assay.
    Antivir Ther. 2017 Mar 6. doi: 10.3851/IMP3151.
    >> Share

  40. BHAGWAT P, Ofotokun I, McComsey GA, Brown TT, et al
    Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.
    Antivir Ther. 2017 Mar 1. doi: 10.3851/IMP3148.
    >> Share

    February 2017
  41. BOESECKE C, Singh GK, Scholten SH, Lutz T, et al
    Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT Study.
    Antivir Ther. 2017 Feb 27. doi: 10.3851/IMP3143.
    >> Share

  42. BISSIO E, Barbas MG, Kademian S, Bouzas MB, et al
    Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3147.
    >> Share

  43. ARENAS-PINTO A, Stohr W, Clarke A, Williams I, et al
    Evaluation of CSF virological escape in patients on long-term PI monotherapy.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3146.
    >> Share

  44. TRAN M, Wood E, Kerr T, Patterson S, et al
    Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3145.
    >> Share

  45. BEHM MO, Yee KL, Fan L, Fackler P, et al
    Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.
    Antivir Ther. 2017 Feb 16. doi: 10.3851/IMP3142.
    >> Share

  46. KREUTZWISER D, Sheehan N, Dayneka N, Lemire B, et al
    Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
    Antivir Ther. 2017 Feb 15. doi: 10.3851/IMP3139.
    >> Share

  47. MOTTA I, Allice T, Romito A, Ferrara M, et al
    Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.
    Antivir Ther. 2017 Feb 15. doi: 10.3851/IMP3140.
    >> Share

  48. BREGIGEON S, Solas C, Faucher O, Obry-Roguet V, et al
    Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
    Antivir Ther. 2017 Feb 14. doi: 10.3851/IMP3137.
    >> Share

  49. LI Y, Xie J, Wang H, Han Y, et al
    Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection.
    Antivir Ther. 2017 Feb 14. doi: 10.3851/IMP3136.
    >> Share

  50. COPPOLA N, De Pascalis S, Messina V, Di Caprio G, et al
    ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
    Antivir Ther. 2017 Feb 6. doi: 10.3851/IMP3134.
    >> Share

    January 2017
  51. SQUIQUERA L, Taxman DJ, Brendle SA, Torres R, et al
    Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study.
    Antivir Ther. 2017 Jan 25. doi: 10.3851/IMP3133.
    >> Share

  52. PORTER DP, Kulkarni R, Garner W, Miller MD, et al
    Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/ tenofovir DF or efavirenz/emtricitabine/ tenofovir DF through 96 weeks.
    Antivir Ther. 2017 Jan 16. doi: 10.3851/IMP3128.
    >> Share

  53. MARGOT N, Cox S, Das M, McCallister S, et al
    Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide or elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Antivir Ther. 2017 Jan 11. doi: 10.3851/IMP3125.
    >> Share

  54. JOTWANI V, Scherzer R, Estrella MM, Jacobson LP, et al
    Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Study.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3124.
    >> Share

  55. JANSSEN S, Huson MA, Osbak KK, Rossatanga EG, et al
    HIV infection rather than concurrent opportunistic infections drives most systemic procoagulant, vascular and damage responses - a prospective cohort study in central Africa.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3100.
    >> Share

  56. TEERAANANCHAI S, Chaivooth S, Kerr SJ, Bhakeecheep S, et al
    Life expectancy after initiation of combination antiretroviral therapy in Thailand.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3121.
    >> Share

  57. SIMONETTI FR, Cattaneo D, Zanchetta N, Giacomet V, et al
    Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for TDM.
    Antivir Ther. 2017 Jan 4. doi: 10.3851/IMP3122.
    >> Share


  58. 19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2017;22.
    >> Share

    December 2016
  59. CATTANEO D, Minisci D, Cozzi V, Riva A, et al
    Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Antivir Ther. 2016 Dec 23. doi: 10.3851/IMP3119.
    >> Share

  60. BENOIT AC, Younger J, Beaver K, Jackson R, et al
    A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada.
    Antivir Ther. 2016 Dec 7. doi: 10.3851/IMP3114.
    >> Share

  61. ROCKSTROH JK, Plonski F, Bansal M, Fatkenheuer G, et al
    Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
    Antivir Ther. 2016 Dec 7. doi: 10.3851/IMP3116.
    >> Share

  62. THOMPSON M, Lalezari JP, Kaplan R, Pinedo Y, et al
    Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Antivir Ther. 2016 Dec 6. doi: 10.3851/IMP3112.
    >> Share

    November 2016
  63. ROCKSTROH JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, et al
    Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Antivir Ther. 2016 Nov 15. doi: 10.3851/IMP3108.
    >> Share

  64. NAICKER N, Naidoo A, Werner L, Garrett N, et al
    Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Antivir Ther. 2016 Nov 4. doi: 10.3851/IMP3106.
    >> Share

  65. GILL VC, Lynch T, Ramazani S, Krentz HB, et al
    Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution.
    Antivir Ther. 2016 Nov 2. doi: 10.3851/IMP3105.
    >> Share

    October 2016
  66. SUDJARITRUK T, Bunupuradah T, Aurpibul L, Kosalaraksa P, et al
    Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.
    Antivir Ther. 2016 Oct 27. doi: 10.3851/IMP3103.
    >> Share

  67. MATOGA MM, Hosseinipour MC, Aga E, Ribaudo HJ, et al
    Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
    Antivir Ther. 2016 Oct 14. doi: 10.3851/IMP3101.
    >> Share

  68. FUNDERBURG NT, Xu D, Playford MP, Joshi AA, et al
    Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.
    Antivir Ther. 2016 Oct 14. doi: 10.3851/IMP3091.
    >> Share

  69. PEREZ-MATUTE P, Pichel JG, Iniguez M, Recio-Fernandez E, et al
    Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity.
    Antivir Ther. 2016 Oct 11. doi: 10.3851/IMP3099.
    >> Share

  70. RANDELL P, Jackson A, Milinkovic A, Boffito M, et al
    An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.
    Antivir Ther. 2016 Oct 6. doi: 10.3851/IMP3098.
    >> Share

  71. COURNIL A, Hema A, Eymard-Duvernay S, Ciaffi L, et al
    Evolution of renal function in African patients initiating second line antiretroviral treatment: findings from the 2LADY-ANRS 12169 trial.
    Antivir Ther. 2016 Oct 5. doi: 10.3851/IMP3097.
    >> Share

    September 2016
  72. MAUSS S, Berger F, Wehmeyer MH, Ingiliz P, et al
    Effect of antiviral therapy for HCV on lipid levels.
    Antivir Ther. 2016 Sep 29. doi: 10.3851/IMP3094.
    >> Share

  73. CAPETTI AF, Orofino G, Sterrantino G, Cossu MV, et al
    Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3095.
    >> Share

  74. KELESIDIS T, Tran TT, Brown TT, Moser C, et al
    Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3093.
    >> Share

  75. PARK MS, Hileman CO, Sattar A, Gilkeson R, et al
    Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults.
    Antivir Ther. 2016 Sep 20. doi: 10.3851/IMP3090.
    >> Share

  76. TESSON T, Blot M, Fillion A, Djerad H, et al
    Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.
    Antivir Ther. 2016 Sep 7. doi: 10.3851/IMP3084.
    >> Share

  77. OLDENBUETTEL C, Wolf E, Ritter A, Noe S, et al
    Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results.
    Antivir Ther. 2016 Sep 2. doi: 10.3851/IMP3082.
    >> Share

  78. GIROMETTI N, Nwokolo N, McOwan A, Whitlock G, et al
    Outcomes of acutely HIV-1-infected individuals following rapid antiretroviral therapy initiation.
    Antivir Ther. 2016 Sep 2. doi: 10.3851/IMP3080.
    >> Share

  79. KHELOUFI F, Poizot-Martin I, Garraffo R, Tavenard A, et al
    ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).
    Antivir Ther. 2016 Sep 1. doi: 10.3851/IMP3074.
    >> Share

    August 2016
  80. BOYD A, Miailhes P, Lascoux-Combe C, Rougier H, et al
    Renal outcomes after up to eight years of tenofovir exposure in HIV-HBV-coinfected patients.
    Antivir Ther. 2016 Aug 24. doi: 10.3851/IMP3076.
    >> Share

  81. NAVARRO J, Curran A, Burgos J, Torrella A, et al
    Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment.
    Antivir Ther. 2016 Aug 22. doi: 10.3851/IMP3075.
    >> Share

  82. MAROCCO R, Lichtner M, Tieghi T, Pozzetto I, et al
    Herpes virus reactivation after initiation of interferon-free antiviral agents in HIV-HCV-coinfected subjects: a new immune restoration disease?
    Antivir Ther. 2016 Aug 8. doi: 10.3851/IMP3072.
    >> Share

    July 2016
  83. BLANCO JR, Jarrin I, Perez-Elias MJ, Gutierrez F, et al
    Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients.
    Antivir Ther. 2016 Jul 28. doi: 10.3851/IMP3071.
    >> Share

  84. SHARMA A, Hoover DR, Shi Q, Holman S, et al
    Falls among middle-aged women in the Women's Interagency HIV Study.
    Antivir Ther. 2016 Jul 18. doi: 10.3851/IMP3070.
    >> Share

    June 2016
  85. D'ALMEIDA KW, Lert F, Spire B, Dray-Spira R, et al
    Determinants of virological response to antiretroviral therapy: socio-economic status still plays a role in the era of cART. Results from the ANRS-VESPA 2 study, France.
    Antivir Ther. 2016 Jun 29. doi: 10.3851/IMP3064.
    >> Share

  86. BELYHUN Y, Maier M, Liebert UG
    HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
    Antivir Ther. 2016 Jun 29. doi: 10.3851/IMP3060.
    >> Share

  87. ARIAS A, Aguilera A, Soriano V, Benitez-Gutierrez L, et al
    Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Antivir Ther. 2016 Jun 24. doi: 10.3851/IMP3061.
    >> Share

  88. NACCARATO M, Hall E, Wai A, Ostrowski M, et al
    A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy.
    Antivir Ther. 2016 Jun 22. doi: 10.3851/IMP3059.
    >> Share

  89. RIVA A, Invernizzi A, Resnati C, Micheli V, et al
    Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?
    Antivir Ther. 2016 Jun 22. doi: 10.3851/IMP3058.
    >> Share

    May 2016
  90. ARCHAMPONG TN, Boyce CL, Lartey M, Sagoe KW, et al
    HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Antivir Ther. 2016 May 11. doi: 10.3851/IMP3055.
    >> Share

    January 2016

  91. 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2016;21 Suppl 1:A1-A63.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016